61 related articles for article (PubMed ID: 11115558)
1. The Multifaceted Functions of Prion Protein (PrP
Abi Nahed R; Safwan-Zaiter H; Gemy K; Lyko C; Boudaud M; Desseux M; Marquette C; Barjat T; Alfaidy N; Benharouga M
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894349
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor.
Ganapathy S; Chen Q; Singh KP; Shankar S; Srivastava RK
PLoS One; 2010 Dec; 5(12):e15627. PubMed ID: 21209944
[TBL] [Abstract][Full Text] [Related]
3. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells.
Fandy TE; Shankar S; Srivastava RK
Mol Cancer; 2008 Jun; 7():60. PubMed ID: 18590557
[TBL] [Abstract][Full Text] [Related]
4. Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis.
Shankar S; Ganapathy S; Chen Q; Srivastava RK
Mol Cancer; 2008 Jan; 7():16. PubMed ID: 18226269
[TBL] [Abstract][Full Text] [Related]
5. Curcumin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells: molecular mechanisms of apoptosis, migration and angiogenesis.
Shankar S; Chen Q; Sarva K; Siddiqui I; Srivastava RK
J Mol Signal; 2007 Oct; 2():10. PubMed ID: 17916240
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells.
Shankar S; Siddiqui I; Srivastava RK
Mol Cell Biochem; 2007 Oct; 304(1-2):273-85. PubMed ID: 17636462
[TBL] [Abstract][Full Text] [Related]
7. Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression.
Abba MC; Drake JA; Hawkins KA; Hu Y; Sun H; Notcovich C; Gaddis S; Sahin A; Baggerly K; Aldaz CM
Breast Cancer Res; 2004; 6(5):R499-513. PubMed ID: 15318932
[TBL] [Abstract][Full Text] [Related]
8. TRAIL/Apo-2L: mechanisms and clinical applications in cancer.
Srivastava RK
Neoplasia; 2001; 3(6):535-46. PubMed ID: 11774036
[TBL] [Abstract][Full Text] [Related]
9. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.
Aggarwal BB; Bhardwaj U; Takada Y
Vitam Horm; 2004; 67():453-83. PubMed ID: 15110190
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
Zhang L; Fang B
Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937
[TBL] [Abstract][Full Text] [Related]
11. Failure of Bcl-2 to block mitochondrial dysfunction during TRAIL-induced apoptosis. Tumor necrosis-related apoptosis-inducing ligand.
Kim EJ; Suliman A; Lam A; Srivastava RK
Int J Oncol; 2001 Jan; 18(1):187-94. PubMed ID: 11115558
[TBL] [Abstract][Full Text] [Related]
12. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways.
Suliman A; Lam A; Datta R; Srivastava RK
Oncogene; 2001 Apr; 20(17):2122-33. PubMed ID: 11360196
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells.
Walczak H; Bouchon A; Stahl H; Krammer PH
Cancer Res; 2000 Jun; 60(11):3051-7. PubMed ID: 10850456
[TBL] [Abstract][Full Text] [Related]
14. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
Kandasamy K; Srinivasula SM; Alnemri ES; Thompson CB; Korsmeyer SJ; Bryant JL; Srivastava RK
Cancer Res; 2003 Apr; 63(7):1712-21. PubMed ID: 12670926
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
